A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors
מצבים רפואיים
Friedreich Ataxia
סיכום בשפה פשוטהבעזרת בינה מלאכותית
הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.
מיקומים
UCLA Neurology, Los Angeles, California, United States
Contact: Principal Investigator (Susan Perlman)University of Colorado, Aurora, Colorado, United States
Contact: Principal Investigator (Trevor Hawkins)University of Florida, Gainesville, Florida, United States
Contact: Principal Investigator (Sub Subramony)Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Contact: Principal Investigator (David Lynch)Medizinische Universität Innsbruck, Innsbruck, Austria
Contact: Principal Investigator (Sylvia Boesch)HUB-Hôpital Erasme, Brussels, Belgium
Contact: Principal Investigator (Naeije Gilles)Center for hereditary ataxias, Motol, Motol, Prague, Czechia
Contact: Principal Investigator (Martin Vyhnalek)Universitätsklinikum Tübingen, Tübingen, Baden-Würtemberg, Germany
Contact: Principal Investigator (Ludger Schöls)University Hospital Aachen, Aachen, Germany
Contact: Principal Investigator (Kathrin Reetz)Klinikum der Universität München, Munich, Germany
Contact: Principal Investigator (Thomas Klopstock)Scientific Institute, IRCCS E. Medea, Conegliano, Italy
Contact: Principal Investigator (Gabriella Paparella)Fondazione I.R.C.C.S. Istituto Neurologico C. Besta, Milan, Italy
Contact: Principal Investigator (Caterina Mariotti)Ospedale Pediatrico Bambino Gesu, Rome, Italy
Contact: Principal Investigator (Gessica Vasco)Stichting Radboud universitair medisch centrum, Nijmegen, Netherlands
Contact: Principal Investigator (Bart van de Warrenburg)
מובילי המחקר
Medical Director
Study Director
Biogen